Magnesium Trial in Acute Asthma: Pediatric Emergency Department Study Data

A randomized double-blind placebo-controlled trial conducted across 6 Canadian pediatric emergency departments, enrolling children aged 2–17 years with acute asthma. The dataset, authored by Suzanne Schuh and last updated on 2026-06-03, contains results from a study investigating the effect of early intravenous magnesium therapy on respiratory distress measured by the Pediatric Respiratory Assessment Measure (PRAM).

Use Cases

• Analyze the effect of intravenous magnesium on Pediatric Respiratory Assessment Measure (PRAM) scores based on the primary outcome described.
• Compare hospitalization rates and asthma re-visits between treatment and placebo groups based on secondary outcomes.
• Model changes in vital signs over a 3-hour period following the intervention based on the study design.
• Assess the statistical power of a sample size of 192 patients for detecting a PRAM difference of ≥1.0 point.

Strengths

• Data originates from a randomized double-blind placebo-controlled trial, a high standard for clinical evidence.
• Study design specifies a sample size of 192 patients, providing a defined scope for analysis.
• Clear primary and secondary outcomes are defined, including PRAM scores, hospitalization, and re-visits.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 5.5 KB, indicating limited scope or summary-level data.

Provenance

Source

figshare, authored by Suzanne Schuh.

Collection Method

Data collected from a randomized controlled trial across 6 Canadian pediatric emergency departments.

Time Range

Temporal coverage is not specified in the input.

Freshness

Last updated 2026-06-03 17:52:40; freshness should be verified.

Geography

Data collected from 6 pediatric emergency departments in Canada.